Treatment and prevention of ocular bacterial infections in Asia part II: The changing landscape of antibiotic treatment

Asian Journal of Ophthalmology

Volumn 10, Issue 5-6, 2008, Pages 388-394

  Espiritu, Cesar R G ^a,b,c  

^a Manila Doctors Hospital   (Philippines)

^b Cataract Section   (Philippines)

^c American Eye Center   (Philippines)

Author keywords

Anti bacterial agents; Asia; Bacterial; Drug resistance; Eye infections; Fluoroquinolones; Therapeutics

Indexed keywords

EID: 58149493683     PISSN: 15602133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Jorgensen JH. Global perspective on antimicrobial resistance in Haemophilus influenzae. J Chemother. 1991;3(Suppl): 155-7.
2. Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens - a global perspective. Semin Respir Infect. 2000;15:195-207.
3. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy. 2004;50(Suppl 1):S3-10.
4. Oncu S, Erdem H, Pahsa A. Therapeutic options for pneumococcal pneumonia in Turkey. Clin Ther. 2005;27:674-83.
5. Applebaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2000;16: 5-15.
6. Bayram A, Balci I. Patterns of antimicrobial resistance in a surgical Intensive care unit of a university hospital in Turkey. BMC Infect Dis. 2006;25:155-60.
7. Suttajit S, Wagner AK, Tantipidoke R, et al. Patterns, appropriateness, and predictors of antimicrobial prescribing for adults with upper respiratory infections in urban slum communities of Bangkok. Southeast Asian J Trop Med Public Health. 2005;36:489-97.
8. Main MW, Memish ZA. Antibiotic resistance. An impending crisis. Saudi Med J. 2000;21:1125-9.
9. Akhter J, Qutub MO, Qadri SM. Antimicrobial susceptibility testing and patterns of resistance at a tertiary care center. Saudi Med J. 2001;22:569-76.
10. Akhter J, Frayha HH, Qadri SM. Current status and changing trends of antimicrobial resistance in Saudi Arabia. J Med Liban. 2000;48:227-32.
11. Nema S, Premchandani P, Asolkar MV, Chitnis DS. Emerging bacterial drug resistance in hospital practice. Indian J Med Sci. 1997;51:275-80.
12. Sharma R, Sharma CL, Kapoor B. Antibacterial resistance: current problems and possible solutions. Indian J Med Sci. 2005;59: 120-9.
13. Wattal C, Joshi S, Sharma A, Oberoi JK, Prasad KJ. Prescription auditing and antimicrobial resistance at a tertiary care hospital in New Delhi, India. J Hosp Infect. 2005;59:156-8.
14. Lee K, Park KH, Jeong SH, et al; KONSAR group. Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance. Yonsei Med J. 2006;47:43-54.
15. Kim WJ, Park SC. Bacterial resistance to antimicrobial agents: an overview from Korea. Yonsei Med J. 1998;39:488-94.
16. Chong Y, Lee K. Present situation of antimicrobial resistance in Korea. J Infect Chemother. 2000;6:189-95.
17. Sirinavin S, Dowell SF. Antimicrobial resistance in countries with limited resources: unique challenges and limited alternatives. Semin Pediatr Infect Dis. 2004; 15:94-8.
18. Parasakthi N. Emerging problems of antibiotic resistance in community medicine. Malays J Pathol. 1996;18:9-13.
19. Kuroyama M, Okamoto E, Yago K. A consideration on the results of nationwide surveillance of antimicrobial susceptibilities - gram-positive cocci and gram-negative cocci. Jpn J Antibiot. 1998;51: 764-8.
20. Takahashi T, Asai T, Kojima A, et al. Present situation of national surveillance of antimicrobial resistance in bacteria isolated from farm animals in Japan and correspondence to the issue. Kansenshogaku Zasshi. 2006;80:185-95. Article in Japanese.
21. Treatment guidelines from The Medical Letter: choice of antibacterial drugs. Med Lett Drugs Ther. 2007;5:33-50.
22. Robert PY, Adenis JP. Comparative review of topical ophthalmic antibacterial preparations. Drugs. 2001;61:175-85.
23. Yorio T, Clark AF, Wax MB, editors. Ocular therapeutics: eye on new discoveries. The Netherlands: Elsevier Academic Press; 2008.
24. Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar). Med Lett Drugs Ther. 2004;46:25-7.
25. Glasser DB, Hyndiuk RA. Antibiotics. In: Lamberts DW, Potter DE, editors. Clinical ophthalmic pharmacology. Boston/Foronto: Little, Brown and Company; 1987. p 53-95.
26. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-5.
27. Mather R, Karenchak LM, Romanowski EG, Kowalski RO. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-6.
28. Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol. 2007;55:15-9.
29. Donaldson KE, Marangon FB, Schatz L, Venkatraman AS, Alfonso EC. The effect of moxifloxacin on the normal human cornea. Curr Med Res Opin. 2006;10:2073-8.
30. McGee DH, Holt WF, Kastner PR, Rice RL. Safety of moxifloxacin as shown in animal and in vitro studies. Survey Ophthalmol. 2005; 50(Suppl):S46-54.
31. Kovoor TA, Kim AS, McCulley JP, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens. 2004;30:90-4.
32. Burka JM, Bower KS, Vanroekel RC, Stutzman RD, Kuzmowych CP, Howard RS. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. Am J Ophthalmol. 2005; 140:83-7.
33. Vigamox product insert. Alcon Laboratories, Fort Worth, Texas; 2004.
34. Gasset AR, Ishii Y, Kaufman HE, Miller T. Cytotoxicity of ophthalmic preservatives. Am J-Ophthalmol. 1974;78:98-105.
35. Tripathi BJ, Tripathi RC. Cytotoxic effects of benzalkonium chloride and chlorobutanol on human corneal epithelial cells in vitro. Lens Eye Toxic Res. 1989;6:395-403.
36. Wagner RS, Abelson MB, Shapiro A, Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol. 2005;123:1282-3.
37. Holland EJ, Lane SS, Kim T, Raizman M, Dunn S. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea. 2008;27: 314-9.
38. Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea. 2005;24:955-8.
39. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005;112:1992-6.
40. Lai WW, Chu KO, Chan KP, et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol. 2007;144: 315-8.
41. McCulley JP, Caudie D, Aronowicz JD, Shine WE. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 2006; 113:955-9.
42. Espiritu CR, Caparas VL, Bolinao JG. Safety of prophylactic intra-cameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg. 2007;33:63-8.
43. Arbisser L. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg. 2008;34:1114-20.
44. Lane SS, Osher RH, Masket S, Belani S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg. 2008;34:1451-9.
45. Ariyasu RG, Nakamura T, Trousdale MD, Smith RE. Intraoperative bacterial contamination of the aqueous humor. Ophthalmic Surg. 1993;24:367-73; discussion 373-4.
46. Mistiberger A, Ruckhofer J, Raithel E, et al. Anterior chamber contamination during cataract surgery with intraocular lens implantation. J Cataract Refract Surg. 1997;23:1064-9.
47. Dickey JB, Thompson KD, Jay WM. Anterior chamber aspirate cultures after uncomplicated cataract surgery. Am J Ophthalmol. 1991;112:278-82.
48. Kowalski RP, Yates KA, Romanowski EG, Karenchak LM, Mah FS, Gordon YJ. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 2005;112:1987-91.
49. Hedlin P, Blondeau JM. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae. Eye Contact Lens. 2007; 33:161-4.
50. Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or parC or gyrA mutation-containing Streptococccus pneumoniae isolates. Antimicrob Agents Chemother. 2004;48:3954-8.
51. Metzler K, Hansen GM, Hedlin P, Harding E, Drlica K, Blondeau JM. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents. 2004;24:161-7.
52. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococccus pneumoniae. Antimicrob Agents Chemother. 2001; 45:433-8.
53. Stroman DW, Cupp G, Dahlin DC, et al. Human ocular concentrations following topical fluoroquinolone administration relative to susceptibility of ocular pathogens. Invest Ophthalmol Vis Sci. 2006;47:ARVO E-abstract 1881.
54. Stroman DW, Dajcs JJ, Cupp GA Schlech BA. In vitro and in vivo potency of moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005;50(Suppl):S16-31.
55. Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol. 2003;121:1229-33.
56. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmaco-dynamics of new quinolones. Eur J Clin Microbiol Infect Dis. 2003; 22:203-21.